The North America Bronchodilators Market would witness market growth of 3.0% CAGR during the forecast period (2022-2028).
Bronchodilators are indicated for patients with lower than optimal airflow through the lungs. The central pillar of the treatment is beta-2 agonists, which target the smooth muscles of the lung’s bronchioles. Numerous respiratory conditions may need bronchodilators, including asthma and chronic obstructive pulmonary disease (COPD). They improve lung functions in patients with COPD or reverse asthma symptoms. For the evaluation of lung functioning, pulmonary function tests are performed.
Bronchodilators are essential in diagnosing and treating lung conditions based on their effect on pulmonary function tests. The FEV1/FVC ratio compares the number of air flows during the first second of the exhalation (forced expiratory volume) to the theoretical amount of air an individual can push out in a maximum exhalation (forced vital capacity).
A typical ratio is 0.7. In reversible increased airway resistance like asthma, pre-bronchodilator pulmonary function tests will generally be less than 0.7. The ratio may be normalized after the administration of a short-acting bronchodilator. However, in nonreversible conditions like chronic obstructive pulmonary disease, giving a short-acting bronchodilator may not normalize the patient pulmonary function test levels.
Around 3.8 million Canadian age one or older were living with asthma in 2011-2012. Also, the number of Canadians living with the disease has risen between 2000-2001 and 2011-2012 due to the chronic nature of the disease. These rising cases of asthma and other lung diseases, coupled with the increasing awareness among the government, will surge the utilization of bronchodilators and thereby propel the market growth in the North America region.
The US market dominated the North America Bronchodilators Market by Country in 2021; thereby, achieving a market value of $8,928.6 million by 2028. The Canada market is experiencing a CAGR of 5.3% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 4.4% during (2022 - 2028).
Based on Drug Class, the market is segmented into Beta-Adrenergic, Xanthine Derivatives, and Anticholinergic. Based on Route of Administration, the market is segmented into Nasal (Inhalable), Oral, and Injectable. Based on Disease, the market is segmented into Asthma, Chronic Obstructive Pulmonary Disease (COPD), and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Bronchodilators Market is Predict to reach $27 Billion by 2028, at a CAGR of 3.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Glenmark Pharmaceuticals Limited, Merck & Co., Inc., GlaxoSmithKline PLC, AstraZeneca PLC, Teva Pharmaceuticals Industries Ltd., Cipla Limited, Viatris, Inc., Novartis AG, Boehringer Ingelheim International GmbH and Sun Pharmaceutical Industries Ltd.
By Drug Class
By Route of Administration
By Disease
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
